SCIENTURE HOLDINGS, INC. Disposal Group, Including Discontinued Operation, Costs of Goods Sold
SCIENTURE HOLDINGS, INC. (SCNX) reported Disposal Group, Including Discontinued Operation, Costs of Goods Sold of $5.06 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold · last filed 2025-03-26
- SCIENTURE HOLDINGS, INC. disposal group, including discontinued operation, costs of goods sold for the quarter ending 2023-12-31 was $4.36M, a 1666.81% increase year-over-year.
- SCIENTURE HOLDINGS, INC. disposal group, including discontinued operation, costs of goods sold for the quarter ending 2023-09-30 was $128.43K, a 59.22% decline year-over-year.
- SCIENTURE HOLDINGS, INC. disposal group, including discontinued operation, costs of goods sold for the quarter ending 2023-06-30 was $306.96K.
- SCIENTURE HOLDINGS, INC. disposal group, including discontinued operation, costs of goods sold for the quarter ending 2023-03-31 was $270.57K.
- SCIENTURE HOLDINGS, INC. disposal group, including discontinued operation, costs of goods sold for fiscal 2023 was $5.06M, a 299.98% increase from fiscal 2022.
- SCIENTURE HOLDINGS, INC. disposal group, including discontinued operation, costs of goods sold for fiscal 2022 was $1.27M.
| Period end | Disposal Group, Including Discontinued Operation, Costs of Goods Sold 3 month | Disposal Group, Including Discontinued Operation, Costs of Goods Sold 3 month as first filed | Disposal Group, Including Discontinued Operation, Costs of Goods Sold 6 month | Disposal Group, Including Discontinued Operation, Costs of Goods Sold 9 month | Disposal Group, Including Discontinued Operation, Costs of Goods Sold 9 month as first filed | Disposal Group, Including Discontinued Operation, Costs of Goods Sold 12 month | Disposal Group, Including Discontinued Operation, Costs of Goods Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | $4.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $4.49M derived: sum of 2 quarters · filed 2025-03-26 | $4.79M derived: sum of 3 quarters · filed 2025-03-26 | $5.06M 10-K · filed 2025-03-26 | $705.21K 10-K · filed 2024-04-22 | ||
| 2023-09-30 | $128.43K 10-Q · filed 2024-11-06 | $127.67K 10-Q · filed 2024-01-16 | $435.39K derived: sum of 2 quarters · filed 2024-11-06 | $705.96K 10-Q · filed 2024-11-06 | $705.21K 10-Q · filed 2024-01-16 | $952.64K derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | $306.96K 10-Q · filed 2024-08-09 | $577.53K 10-Q · filed 2024-08-09 | $824.22K derived: sum of 3 quarters · filed 2024-08-09 | $1.14M derived: sum of 4 quarters · filed 2024-08-09 | |||
| 2023-03-31 | $270.57K 10-Q · filed 2024-06-26 | $517.25K derived: sum of 2 quarters · filed 2024-06-26 | $832.20K derived: sum of 3 quarters · filed 2024-06-26 | ||||
| 2022-12-31 | $246.68K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-22 | $561.63K derived: sum of 2 quarters · filed 2024-04-22 | $1.27M 10-K · filed 2024-04-22 | ||||
| 2022-09-30 | $314.94K 10-Q · filed 2024-01-16 | $1.02M 10-Q · filed 2024-01-16 | |||||
| 2016-09-30 | $230.67K 10-Q · filed 2017-11-07 | $1.27M derived: sum of 2 quarters · filed 2017-11-07 | $2.27M 10-Q · filed 2017-11-07 | ||||
| 2016-06-30 | $1.04M 10-Q · filed 2017-08-04 | $2.04M 10-Q · filed 2017-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |